Reimbursement price and discounts – Drug prices in Germany
You might be familiar with the price negotiations to derive the reimbursement price, but this does not always reflect the final, real-world
Tag: AMNOG process
Why did the G-BA assess Trimbow now?
Trimbow was launched onto the German market in 2017. So why did the G-BA assess its benefit now? You likely know that
Pricing in Germany: How is the reimbursed price of a drug set?
At the time of launch in the German market, pharmaceutical companies are free to set the price for their product with a
First COVID-19 drug has been assessed by G-BA
The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It
What is reference pricing?
If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,